Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model
- 1 April 2006
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 101 (1) , 46-54
- https://doi.org/10.1016/j.ygyno.2005.09.053
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Elimination of Hepatic Metastases of Colon Cancer Cells via p53-Independent Cross-Talk between Irinotecan and Apo2 Ligand/TRAILCancer Research, 2004
- Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugsGynecologic Oncology, 2004
- Apo2 Ligand/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve SurvivalCancer Research, 2004
- Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cellsGynecologic Oncology, 2004
- Chemotherapy induces death receptor 5 in epithelial ovarian carcinomaGynecologic Oncology, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cellsInternational Journal of Cancer, 2003
- Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer TherapyJournal of Clinical Oncology, 2003
- Synergistic Induction of Apoptosis by the Combination of TRAIL and Chemotherapy in Chemoresistant Ovarian Cancer CellsGynecologic Oncology, 2001
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999